Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab for sickle cell disease-associated chronic kidney disease
PACTR202006732730001Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in sickle cell nephropathy (SCN), chronic kidney disease (CKD) and sickle cell disease (SCD) comparing Crizanlizumab with Placebo comparator (2 arms). Primary endpoint: Proportion of patients with at least 30% decrease in ACR at 12 months. Started Oct 2020; status: recruiting.
02
Drugs
crizanlizumab
03
Conditions
sickle cell nephropathy (SCN)chronic kidney disease (CKD)sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202006732730001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202006732730001.